RhumbLine Advisers’s Antares Pharma, Inc. ATRS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q2 | – | Sell |
-188,475
| Closed | -$773K | – | 3341 |
|
|
2022
Q1 | $773K | Sell |
188,475
-138
| -0.1% | -$501 | ﹤0.01% | 2234 |
|
|
2021
Q4 | $673K | Sell |
188,613
-71,322
| -27% | -$249K | ﹤0.01% | 2385 |
|
|
2021
Q3 | $946K | Sell |
259,935
-24,719
| -9% | -$99.9K | ﹤0.01% | 2241 |
|
|
2021
Q2 | $1.24M | Buy |
284,654
+17,518
| +7% | +$71.4K | ﹤0.01% | 2148 |
|
|
2021
Q1 | $1.1M | Sell |
267,136
-13,680
| -5% | -$59.3K | ﹤0.01% | 2153 |
|
|
2020
Q4 | $1.12M | Buy |
280,816
+19,855
| +8% | +$64.2K | ﹤0.01% | 2084 |
|
|
2020
Q3 | $705K | Sell |
260,961
-17,780
| -6% | -$49.2K | ﹤0.01% | 2133 |
|
|
2020
Q2 | $767K | Buy |
278,741
+57,091
| +26% | +$159K | ﹤0.01% | 2157 |
|
|
2020
Q1 | $523K | Sell |
221,650
-1,100
| -0.5% | -$3.74K | ﹤0.01% | 2146 |
|
|
2019
Q4 | $1.05M | Buy |
222,750
+9,304
| +4% | +$38.1K | ﹤0.01% | 2058 |
|
|
2019
Q3 | $714K | Sell |
213,446
-1,575
| -0.7% | -$5.19K | ﹤0.01% | 2185 |
|
|
2019
Q2 | $707K | Buy |
215,021
+31,316
| +17% | +$90.6K | ﹤0.01% | 2219 |
|
|
2019
Q1 | $557K | Sell |
183,705
-3,158
| -2% | -$10.2K | ﹤0.01% | 2289 |
|
|
2018
Q4 | $508K | Buy |
186,863
+62,857
| +51% | +$207K | ﹤0.01% | 2291 |
|
|
2018
Q3 | $417K | Sell |
124,006
-9,235
| -7% | -$28.5K | ﹤0.01% | 2350 |
|
|
2018
Q2 | $344K | Buy |
133,241
+10,425
| +8% | +$25.9K | ﹤0.01% | 2466 |
|
|
2018
Q1 | $270K | Sell |
122,816
-1,800
| -1% | -$4.05K | ﹤0.01% | 2490 |
|
|
2017
Q4 | $248K | Sell |
124,616
-25,672
| -17% | -$55.9K | ﹤0.01% | 2539 |
|
|
2017
Q3 | $487K | Buy |
150,288
+3,363
| +2% | +$10.4K | ﹤0.01% | 2317 |
|
|
2017
Q2 | $473K | Buy |
+146,925
| New | +$416K | ﹤0.01% | 2330 |
|
|
2016
Q2 | – | Sell |
-150,355
| Closed | -$131K | – | 3042 |
|
|
2016
Q1 | $131K | Hold |
150,355
| – | – | ﹤0.01% | 2846 |
|
|
2015
Q4 | $182K | Buy |
150,355
+14,005
| +10% | +$19.5K | ﹤0.01% | 2832 |
|
|
2015
Q3 | $232K | Buy |
136,350
+4,302
| +3% | +$8.43K | ﹤0.01% | 2702 |
|
|
2015
Q2 | $275K | Buy |
132,048
+13,440
| +11% | +$32.6K | ﹤0.01% | 2716 |
|
|
2015
Q1 | $321K | Buy |
118,608
+22,650
| +24% | +$57.5K | ﹤0.01% | 2573 |
|
|
2014
Q4 | $247K | Buy |
95,958
+2,825
| +3% | +$6.35K | ﹤0.01% | 2688 |
|
|
2014
Q3 | $170K | Hold |
93,133
| – | – | ﹤0.01% | 2813 |
|
|
2014
Q2 | $249K | Sell |
93,133
-1,832
| -2% | -$5.51K | ﹤0.01% | 2709 |
|
|
2014
Q1 | $332K | Sell |
94,965
-5,500
| -5% | -$24.4K | ﹤0.01% | 2469 |
|
|
2013
Q4 | $450K | Sell |
100,465
-7,300
| -7% | -$29.7K | ﹤0.01% | 2320 |
|
|
2013
Q3 | $438K | Buy |
107,765
+5,903
| +6% | +$25.8K | ﹤0.01% | 2299 |
|
|
2013
Q2 | $424K | Buy |
+101,862
| New | +$393K | ﹤0.01% | 2379 |
|
Other funds holding ATRS
RhumbLine Advisers's ATRS Position: Q2 2022 in Review
RhumbLine Advisers sold out of Antares Pharma, Inc. (ATRS) in Q2 2022, closing a stake of 188,475 shares — an estimated $773K sold.
RhumbLine Advisers first reported a position in ATRS in Q2 2013 and held it in 32 quarters. The position peaked at $1.24M in Q2 2021. 1 fund tracked by Wall St. Rank holds ATRS as of Q2 2022.
- RhumbLine Advisers reported no remaining Antares Pharma, Inc. position as of Q2 2022 after selling out during the quarter.
- RhumbLine Advisers sold 188,475 Antares Pharma, Inc. shares in Q2 2022, an estimated $773K.
- RhumbLine Advisers first reported a position in Antares Pharma, Inc. in Q2 2013 and held it in 32 quarters.
- RhumbLine Advisers's Antares Pharma, Inc. position peaked at $1.24M in Q2 2021.
- 1 fund tracked by Wall St. Rank held Antares Pharma, Inc. as of Q2 2022.
Based on RhumbLine Advisers's 13F filing for Q2 2022, filed 11 Aug 2022.